Filing Details

Accession Number:
0001293301-14-000007
Form Type:
4
Zero Holdings:
No
Publication Time:
2014-01-27 16:52:18
Reporting Period:
2014-01-24
Filing Date:
2014-01-27
Accepted Time:
2014-01-27 16:52:18
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
38074 Forest Laboratories Inc FRX Pharmaceutical Preparations (2834) 111798614
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1224339 Howard Solomon C/O Forest Laboratories, Inc.
909 Third Avenue
New York NY 10022
Yes No No No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Common Stock Disposition 2014-01-24 185,182 $65.27 529,699 No 4 S Direct
Common Stock Disposition 2014-01-24 37,527 $66.48 492,172 No 4 S Direct
Common Stock Disposition 2014-01-24 5,547 $67.05 486,625 No 4 S Direct
Common Stock Disposition 2014-01-27 21,744 $64.32 464,881 No 4 S Direct
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 S Direct
No 4 S Direct
No 4 S Direct
No 4 S Direct
Footnotes
  1. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $65.00 to $65.90, inclusive. The Reporting Person undertakes to provide to the Company, any security holder of the Company, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote.
  2. This amount includes shares of common stock which are subject to a risk of forfeiture.
  3. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $66.01 to $66.97, inclusive. The Reporting Person undertakes to provide to the Company, any security holder of the Company, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote.
  4. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $67.00 to $67.23, inclusive. The Reporting Person undertakes to provide to the Company, any security holder of the Company, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote.
  5. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $64.03 to $64.67, inclusive. The Reporting Person undertakes to provide to the Company, any security holder of the Company, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote.